Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis.

Sahinkoc M, Nemutlu GS, El-Serag HB, Peters MLB, Hajjar A, Samir AE, Dageforde LA, Kanwal F, Chhatwal J

DOI: 10.1097/hc9.0000000000001005
Published: 2026 Aug 1
Container: Hepatology communications
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hc9.0000000000001005,
  title = {Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis.},
  author = {Sahinkoc M and Nemutlu GS and El-Serag HB and Peters MLB and Hajjar A and Samir AE and Dageforde LA and Kanwal F and Chhatwal J},
  year = {2026},
  journal = {Hepatology communications},
  doi = {10.1097/hc9.0000000000001005},
  url = {https://doi.org/10.1097/hc9.0000000000001005}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis.
AU  - Sahinkoc M
AU  - Nemutlu GS
AU  - El-Serag HB
AU  - Peters MLB
AU  - Hajjar A
AU  - Samir AE
AU  - Dageforde LA
AU  - Kanwal F
AU  - Chhatwal J
PY  - 2026
JO  - Hepatology communications
DO  - 10.1097/hc9.0000000000001005
UR  - https://doi.org/10.1097/hc9.0000000000001005
ER  -

APA

M, S., GS, N., HB, E., MLB, P., A, H., AE, S., LA, D., F, K., & J, C. (2026). Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis.. Hepatology communications. https://doi.org/10.1097/hc9.0000000000001005

Source records

pubmed · retrieved 2026-09-26T12:14:02.549Z